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Abstract
Identification of breast cancer stem cells as the cells within breast
tumors that have the ability to give rise to cells that make up the
bulk of the tumor mass has shifted the focus of cancer research.
However, there is still much debate concerning the unique nature
of the markers that distinguish cancer stem cells in the breast. As
such, understanding whether CD44+/CD24- breast cancer cells
are merely more successful in overcoming an engraftment
incompatibility that exists when injecting human cells into the
mouse adipose tissue or are indeed bona fide cancer stem cells is
of great importance.
Introduction
Although the theory of cancer stem cells dates back more
than 50 years, the existence of the first bona fide tumorigenic
cell compartment was not demonstrated until 1994, when the
acute myelogenous leukemia stem cell (LSC) was identified
and characterized [1]. Since then, despite accumulating
evidence that LSCs are responsible for maintenance and
transfer of blood cancers, researchers doubted the existence
of an analogous cell type in solid tumors. In fact, it was
believed that every cell from a tumor had an equal likelihood
of seeding a secondary cancer as long as it was in the
correct microenvironment. However, in 2003 an influential
report describing the prospective identification of human
breast cancer stem cells changed the landscape of breast
cancer research [2]. Using various human tumor samples
(eight pleural effusions and one primary tumor), which were
xenografted into the mammary glands of nonobese diabetic/
severe combined immunodeficient mice, the investigators
reported that a small population of CD44+/CD24-/Lin- human
breast cancer cells were enriched for tumorigenic potential.
Most researches now consider that, like leukemia, solid
tumors such as prostate, breast, colon, brain, and pancreatic
cancers contain a small fraction of self-renewing tumorigenic
cells that give rise to and maintain the bulk of the tumor mass.
The use of Hoescht dye efflux, suspension sphere assays,
and serial transplantation are all proposed methods for
identifying and separating cancer stem cells from solid
tumors. However, arguably the most effective method of
identifying these cells, which may be morphologically
indistinct from the bulk of the cancer, is through differential
cell surface protein expression.
The choice and relevance of solid tumor
markers
The relevance of current cancer stem cell markers for solid
tumors remains controversial and perplexing. In leukemia, the
rationale for using the cell surface makers CD34+/CD38- to
identify LSCs was based on the known and shared markers
for hematopoietic stem cells. However, in the case of breast
cancer, the rationale for selection of prospective markers is
less clear, primarily because the human breast stem cell has
not yet been extensively characterized. Although a putative
murine mammary stem cell was recently reported [3,4], the
markers used in these studies have yet to be applied to
human breast cancer stem cells. More importantly, even if
researchers do apply the mouse markers to human cells,
lessons learned from the hematopoietic field would suggest
that the markers in mouse may not translate to humans (for
instance, CD38 and Sca1).
For solid tumors, the repertoire of cell surface markers
currently used to identify human cancer stem cells includes
CD44, CD133, epithelial surface antigen (ESA), and CD24,
either singly or in combination. Specifically, the CD44+
phenotype is correlated positively with colon, breast,
prostate, and pancreatic cancer initiator cells [2,5-7].
Likewise, CD133+ cells have been shown to initiate human
glioblastoma, colon, prostate, and pancreatic cancers in mice
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[5-8]. The phenotype of pancreatic and breast cancer initiator
cells and normal breast progenitor cells is ESA+ [2,7,9].
Finally, CD24 has a more ambiguous past because it is
positively correlated with tumorigenicity in pancreatic cancer
[7] but negatively correlated in breast cancer [2], yet CD24+
cells are associated with invasive breast cancer [10].
The functional significance of these proteins is an area of
investigation that remains poorly understood. It has been
suggested that CD44 is an important molecule for metastasis
because a nonmetastatic rat glioma cell line acquired meta-
static properties when a splice variant of CD44 was
ectopically over-expressed [11]. In addition, CD44 variant
isoforms are differentially expressed during pregnancy and
involution, indicating a role in normal breast epithelial homeo-
stasis [12]. ESA is another molecule that deserves further
investigation because it was shown to be essential for
migration and invasion of the human breast cancer cell line
MDA.MB.231 [13].
Regardless of the biologic activities of these markers, it is
remarkable that the same cell surface markers enrich for
tumor stem cells across many solid tumor types. Therefore,
perhaps the markers that are currently used to identify ‘stem
cells’ from solid tumors could actually be enriching for cells
with certain functional properties in vivo or in vitro, namely to
engraft successfully in mouse or to adhere and expand in
culture. This theory is supported by the fact that nearly all
studies on the prospective identification of human solid tumor
stem cells have either xenografted the primary tumor into a
nonobese diabetic/severe combined immunodeficient mouse,
or briefly conditioned the tumor cells in culture before
enriching for tumor initiating cells [2,5-7].
What defines a cancer stem cell?
The definition of a stem cell is the ability to self-renew and
give rise to a daughter cell that is different from itself. The
‘gold standard’ in demonstrating stem cell activity is the ability
to reconstitute a diverse tissue in vivo (normal or malignant).
Although this is straightforward when studying murine stem
cells, because the mouse serves as the natural host for
engraftment studies, it is more complex when the only means
for defining a human cancer stem cell is its ability to engraft in
a mouse. Thus, if a cancer cell cannot successfully engraft
into a mouse because of a species, hormonal, or micro-
environment incompatibility, does this mean that the cell is
not a cancer stem cell?
The importance of microenvironment was recently illustrated
in an elegant study with leukemia [14]. In this study, murine
LSCs deficient for CD44 introduced into the circulation of
mice were unable to home to the bone marrow and thus
could not form leukemia. However, the same CD44-deficient
LSCs injected directly into the bone marrow were fully able to
engraft and regenerate a heterogeneous tumor. Based on
this work, it is clear that cancer stem cells that give rise to a
heterogeneous tumor can exist, but if that same cell cannot
engraft because of an incompatible microenvironment, should
it no longer be defined as a cancer stem cell?
For human breast cancers, is it the case that CD44+/CD24-
cells are simply better at engrafting in the mouse mammary
microenvironment, or are they really more tumorigenic in the
human setting? The murine mammary gland is an excellent
site for transplantation of primary mouse mammary epithelial
cells (normal and neoplastic) because it is the natural stromal
microenvironment for murine mammary cells. However,
attempts to introduce human mammary epithelial cells
(normal or malignant) into mouse mammary fat pads were
only successful when the fibrous stroma of the human breast
was recreated [15-17]. Because the stromal cells that are
adjacent to cancer cells can facilitate their engraftment and
tumor formation [16,18,19], it is plausible that CD44+/CD24-
breast cancer cells are merely the cells that are the most
successful in overcoming an engraftment incompatibility that
exists when injecting human cells into the mouse adipose
stroma.
The relevance of CD44 and CD24 in human
breast cancer
Several studies that have attempted to repeat and expand on
the CD44+/CD24- breast cancer initiator cell profile have
thus far been inconclusive. In 2004, a clinical study reported
that there was no statistically significant CD44 or CD24
staining in primary breast cancer sections in relation to tumor
grade, type, or size [20]. The authors postulated that one
difference is that they use primary sections, in which a
pathologist can identify tumor tissue, whereas in their study
Al-Hajj and coworkers [2] used cell sorting to remove Lin-
cells and subsequent flow cytometry. However, two more
recent reports [21,22] have now confirmed, both in breast
cancer derived cell lines and breast tumors, that
CD44+/CD24- phenotypes are not necessarily associated
with patient outcome or ability to metastasize.
In recent work, Shipitsin and coworkers [22] found that
CD24 is expressed on more differentiated cells whereas
CD44 is expressed on more progenitor-like cells. Specifically,
they found that breast cells of the CD44+/CD24- phenotype
express genes that are involved in cell motility and angio-
genesis, are more mesenchymal, are motile, and are pre-
dominately estrogen receptor negative. In agreement with this
study, we and others have also observed a strong association
between breast cancer cells with a basal-like or mesen-
chymal-like phenotype (MDA.MB.231, SUM159, SUM1315)
and the presence CD44+/CD24- cells (unpublished data,
[21]). In contrast, cells with a more luminal, epithelial
appearance (MCF7 and SUM225) were largely CD44-/
CD24+, which is consistent with the luminal differentiated
mucin-1-positive, estrogen receptor/progesterone receptor-
positive, Gata3-positive cells reported by Shipitsin and
coworkers. Taken together, these studies suggest anotherPage 3 of 3
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interesting interpretation of CD24 and CD44 as markers of
breast cancer cells; perhaps CD44+ cells are predominately
basal-like and therefore are present in poor prognosis basal-
like tumors, whereas CD24+ cells are luminal-like and
therefore present in more differentiated luminal-type cancers.
Conclusion
With the aim being to eradicate breast cancer, there is great
interest and excitement in the possibility of identifying and
treating the subpopulation of cancer stem cells that fuel
tumor growth. However, there remains a need to determine
whether CD44+/CD24- cells are true tumorigenic cells
across all the various breast cancer subtypes, or whether
these are unique to a more basal tumor type. Fortunately, the
field is growing with the identification of new potential
markers, such as protein C receptor [20], which may permit
further enrichment and identification of therapeutic targets for
treatment of breast cancer.
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